Listen • 5:27
Carlene Knight, 54, is one of the first patients in a landmark study designed to try to restore vision in those who have a rare genetic disease that causes blindness.
Carlene Knight would love to do things that most people take for granted, such as read books, drive a car, ride a bike, gaze at animals in a zoo and watch movies. She also longs to see expressions on people s faces. To be able to see my granddaughter especially my granddaughter s face, said Knight, 54, who lives outside Portland, Ore. It would be huge.
Michael Kalberer yearns to be able to read a computer screen so he could get back to work as a social worker. He also hopes to one day watch his nieces and nephews play soccer instead of just listening to them, and move around in the world without help. But that s not all.
Baricitinib Continuation Rate High in Real-World Practice medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern
Researchers in the United States have conducted a study demonstrating the effectiveness of first-generation vaccines at protecting against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals who have previously been infected with the virus.
The novel SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to pose a threat to global public health and has now claimed the lives of more than 3.19 million people worldwide.
The team assessed levels of neutralizing antibodies against variants of SARS-CoV-2 before and after two doses of the Pfizer-BioNTech vaccine in ten individuals who had been infected with the original strain of the virus prior to vaccination. These neutralizing titers were compared with those of people who also received the two vaccines but had not previously been infected.
email article
Stereotactic body radiotherapy (SBRT) proved safe for treating cancer patients with multiple metastases, according to a phase I trial.
In the NRG-BR001 trial, standard doses of SBRT were safe in 35 patients with oligometastatic breast, prostate, and non-small cell lung cancer (NSCLC) with a median of three or four metastases, or two within proximity to each other, reported Steve Chmura, MD, PhD, of University of Chicago Medicine, and colleagues.
Also, there were no protocol-defined dose-limiting toxicities in these patients at 180 days after the initiation of therapy, they stated in
However, the authors noted that a number of patients experienced late grade 3 adverse events (AEs), most likely related to the protocol therapy, which demonstrated the need for long-term follow-up with these patients.
Mysterious Ailment, Mysterious Relief: Vaccines Help Some Covid Long Haulers physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.